Gleeson Laura E, Waterer Grant
Dept of Clinical Medicine, Trinity College School of Medicine, Dublin, Ireland.
School of Medicine, University of Western Australia, Perth, Australia.
Breathe (Sheff). 2022 Jun;18(2):210171. doi: 10.1183/20734735.0171-2021. Epub 2022 Jul 12.
Nontuberculous mycobacteria (NTM) pulmonary disease represents a significant clinical challenge with suboptimal therapy and increasing prevalence globally. Although clinical practice guidelines seek to standardise the approach to diagnosis and treatment of NTM disease, a lack of robust evidence limits their utility and significant variability exists in clinical practice. Here we walk through some novel approaches in diagnosis and therapy that are under development to tackle a disease where traditional strategies are failing.
To recognise the growing prevalence and importance of NTM pulmonary disease globally.To identify shortfalls in current diagnostic and therapeutic strategies, and highlight the challenges that must be addressed in future research and development efforts.To appreciate the role of novel therapeutic approaches such as immunomodulation of host defence, and to explore some examples of burgeoning therapies.
非结核分枝杆菌（NTM）肺病是一项重大的临床挑战，治疗效果欠佳且在全球范围内患病率不断上升。尽管临床实践指南试图规范NTM病的诊断和治疗方法，但缺乏有力证据限制了其效用，临床实践中仍存在显著差异。在此，我们探讨一些正在开发的诊断和治疗新方法，以应对传统策略失效的疾病。
认识到NTM肺病在全球范围内日益增长的患病率和重要性。识别当前诊断和治疗策略的不足，并强调未来研发工作中必须解决的挑战。理解宿主防御免疫调节等新型治疗方法的作用，并探索一些新兴疗法的实例。
